Vimentin Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value | [1]
|----------|-------| [2]
| Category | Glial Activation Marker, Intermediate Filament | [3]
| Target | Vimentin (VIM) | [4]
| Sample Type | CSF, Blood, Tissue | [5]
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Gliomas | [6]
| Role | Intermediate filament, reactive astrocyte marker | [7]
| Gene | VIM | [8]
| Protein | Vimentin Protein | [9]
Vimentin is a type III intermediate filament protein expressed predominantly in mesenchymal cells, reactive astrocytes, activated microglia, and Schwann cells PMID: 20012068. It serves as a sensitive marker of glial activation and cellular stress in the central nervous system, with expression dramatically upregulated following CNS injury, neurodegeneration, and inflammation PMID: 25287859. [10]
The VIM gene is located on chromosome 10p13 and encodes a 466-amino acid protein (57 kDa) that polymerizes to form 10 nm intermediate filaments PMID: 6309119. The protein structure consists of: [11]
In the healthy brain, vimentin expression is limited to: [12]
Following CNS injury or in neurodegenerative disease, vimentin is dramatically upregulated in reactive astrocytes, forming part of the glial scar response PMID: 20012068. This upregulation is coordinated with GFAP and nestin, forming a network of intermediate filaments characteristic of the reactive astrocyte phenotype PMID: 25975510. [13]
Vimentin intermediate filaments provide mechanical stability to cells and participate in: [14]
Beyond structural roles, vimentin participates in multiple signaling pathways:
| Function | Mechanism | Relevance to Neurodegeneration |
|---|---|---|
| Cell migration | Regulates focal adhesion dynamics PMID: 16951002 | Astrocyte migration to injury sites |
| Wound healing | Coordinates scar formation PMID: 15548597 | Glial scar in CNS trauma |
| Signal transduction | Interacts with MAPK, PKC pathways PMID: 12949735 | Inflammatory signaling |
| Cell cycle regulation | Phosphorylation during mitosis PMID: 2037528 | Glial proliferation |
| Apoptosis regulation | Cleavage by caspases PMID: 9748272 | Neuronal death pathways |
Vimentin undergoes extensive post-translational modification that regulates its function:
Vimentin serves as a biomarker of astrocyte activation in Alzheimer's Disease:
Mechanistically, vimentin upregulation in AD reflects:
In Parkinson's Disease, vimentin expression correlates with disease pathology:
Vimentin is significantly upregulated in ALS:
In Multiple Sclerosis, vimentin marks active disease processes:
| Method | Sensitivity | Advantages | Limitations |
|---|---|---|---|
| ELISA | High | Quantitative, standardized | Cross-reactivity with related proteins |
| Western Blot | Moderate | Specific size detection | Semi-quantitative |
| Mass Spectrometry | Very High | Multiple isoforms detected | Expensive, specialized |
| Simoa | Ultra-sensitive | Single molecule detection | Limited availability |
| Luminex | High | Multiplex panels available | Requires standardization |
Vimentin's primary diagnostic value lies in:
Vimentin is most useful when combined with other biomarkers:
Several therapeutic strategies target vimentin in neurodegeneration:
| Approach | Mechanism | Status |
|---|---|---|
| Vimentin knockdown | siRNA reduces astrocyte reactivity PMID: 23671134 | Preclinical |
| Withaferin A | Natural compound disrupting vimentin filaments PMID: 2037528 | Preclinical |
| Anti-vimentin antibodies | Imaging of activated astrocytes PMID: 12949735 | Research tool |
| Phosphorylation inhibitors | Target kinases regulating vimentin dynamics | Conceptual |
Vimentin interacts with several proteins central to neurodegeneration:
Vimentin plays a central role in cellular stress responses:
| Disease | Vimentin Change | Clinical Utility | Key Findings |
|---|---|---|---|
| AD | ↑ CSF and tissue | Progression marker | Correlates with cognition, plaques |
| PD | ↑ Substantia nigra | Pathology marker | Colocalizes with Lewy bodies |
| ALS | ↑↑ CSF and tissue | Progression marker | TDP-43 interaction |
| MS | ↑↑ Active lesions | Disease activity | BBB disruption marker |
| Glioma | ↑↑↑ Tumor cells | Diagnostic | Diagnostic marker |
The study of Vimentin Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. 2014. ↩︎
Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. 2015. ↩︎
Middeldorp J, Hol EM. GFAP in health and disease. 2011. ↩︎
Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. 2015. ↩︎
Quax WJ, et al. Characterization of the human vimentin gene. 1983. ↩︎
Herrmann H, Aebi U. Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular scaffolds. 2004. ↩︎
Ivaska J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. 2007. ↩︎
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. 2011. ↩︎
Thygesen C, et al. CSF and blood biomarkers in neurodegenerative diseases. 2015. ↩︎
Wilhelmsson U, et al. The role of GFAP and vimentin in reactive astrocytes. 2016. ↩︎
Eriksson JE, et al. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. 2004. ↩︎
Byun Y, et al. Caspase cleavage of vimentin disrupts intermediate filaments during apoptosis. 2001. ↩︎
Sánchez G, et al. Role of vimentin in neuronal development. 1994. ↩︎
Pekny M, et al. Vimentin knockout leads to reduced glial scar formation and improved neuronal survival after brain injury. 1999. ↩︎